{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:35:42Z","timestamp":1784734542098,"version":"3.55.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>This study aimed at assessing the impact of surgical treatments in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A propensity score-matched analysis based on data in the Surveillance, Epidemiology, and End Results database was used to assess the efficacy of surgical treatment in patients with GEP-NETs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 7515 patients diagnosed with GEP-NETs from 2004 to 2015 were evaluated from the Surveillance, Epidemiology, and End Results database. There were 1483 patients in the surgery group and 6032 patients in the nonsurgery group. Compared with patients in the surgery group, patients in the nonsurgery group were inclined to receive chemotherapy (50.8 vs. 16.7%) and radiation (12.9 vs. 3.7%) as treatment options. Multivariate Cox regression analysis revealed higher rates of overall survival (OS) outcomes for GEP-NETs patients who had been subjected to surgery (hazard ratio=0.483, 95% CI=0.439\u20130.533, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). Then, to reduce the impact of bias, a 1\u00a0:\u00a01 propensity score-matched analysis was performed for the two groups of patients. A total of 1760 patients were assessed and each subgroup included 880 patients. In the matched population, the patients exhibited the ability to significantly benefit from surgery (hazard ratio=0.455, 95% CI=0.439\u20130.533, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). The OS outcomes for radiation or chemotherapy patients who had been treated with surgery were better than those of patients who had not been treated with surgery (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001). In addition, it was found that the OS of patients was not significant after rectum and small intestine surgery, whereas there was a significant difference in OS after colon, pancreas, and stomach surgery on the patients. Patients who had been subjected to surgery in the rectum and small intestines exhibited better therapeutic benefits.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Patients with GEP-NETs who are treated with surgery have better OS outcomes. Therefore, surgery is recommended for specified selected patients with metastatic GEP-NETs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/js9.0000000000000336","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T13:00:12Z","timestamp":1683118812000},"page":"1629-1638","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["The impact of surgery and survival prediction in patients with gastroenteropancreatic neuroendocrine tumors: a population-based cohort study"],"prefix":"10.1097","volume":"109","author":[{"given":"Zenghong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3779-8733","authenticated-orcid":false,"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1335-5295","authenticated-orcid":false,"given":"Mengke","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6]]},"reference":[{"key":"R1-20250824","doi-asserted-by":"crossref","first-page":"8123","DOI":"10.3748\/wjg.v27.i47.8123","article-title":"Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: a new category in the World Health Organization classification","volume":"27","author":"Xu","year":"2021","journal-title":"World J Gastroenterol"},{"key":"R2-20250824","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"R3-20250824","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1002\/cam4.1598","article-title":"Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: a large population-based study","volume":"7","author":"Zhong","year":"2018","journal-title":"Cancer Med"},{"key":"R4-20250824","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.gtc.2022.06.002","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"51","author":"Fernandes","year":"2022","journal-title":"Gastroenterol Clin North Am"},{"key":"R5-20250824","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00262-021-03046-8","article-title":"Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NETs): a 2021 update","volume":"71","author":"Kole","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"R6-20250824","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/jnci\/djn275","article-title":"Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors","volume":"100","author":"Modlin","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R7-20250824","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/DCR.0000000000000298","article-title":"Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis","volume":"58","author":"Shafqat","year":"2015","journal-title":"Dis Colon Rectum"},{"key":"R8-20250824","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.radonc.2013.01.008","article-title":"Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma","volume":"106","author":"Meng","year":"2013","journal-title":"Radiother Oncol"},{"key":"R9-20250824","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.21037\/jtd.2016.04.21","article-title":"Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection","volume":"8","author":"Deng","year":"2016","journal-title":"J Thorac Dis"},{"key":"R10-20250824","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"R11-20250824","doi-asserted-by":"crossref","first-page":"106165","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery","volume":"96","author":"Mathew","year":"2021","journal-title":"Int J Surg"},{"key":"R12-20250824","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/PAS.0b013e31828ff59d","article-title":"Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis","volume":"37","author":"Ishida","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R13-20250824","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1245\/s10434-015-5013-2","article-title":"Surgical treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma: a nordic multicenter comparative study","volume":"23","author":"Haugvik","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R14-20250824","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8<1366::AID-CNCR2>3.0.CO;2-D","article-title":"Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis","volume":"80","author":"Casas","year":"1997","journal-title":"Cancer"},{"key":"R15-20250824","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1245\/s10434-014-3725-3","article-title":"A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum","volume":"21","author":"Smith","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R16-20250824","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R17-20250824","doi-asserted-by":"crossref","first-page":"17588359211018047","DOI":"10.1177\/17588359211018047","article-title":"Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors","volume":"13","author":"Das","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"R18-20250824","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.path.2019.08.011","article-title":"Treatment of gastroenteropancreatic neuroendocrine tumors","volume":"12","author":"Perez","year":"2019","journal-title":"Surg Pathol Clin"},{"key":"R19-20250824","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/MPA.0b013e3181ebb56f","article-title":"North American neuroendocrine tumor society (NANETS). The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas","volume":"39","author":"Strosberg","year":"2010","journal-title":"Pancreas"},{"key":"R20-20250824","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000443172","article-title":"Vienna consensus conference participants. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas","volume":"103","author":"Garcia-Carbonero","year":"2016","journal-title":"Neuroendocrinology"},{"key":"R21-20250824","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R22-20250824","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","article-title":"The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems","volume":"39","author":"Klimstra","year":"2010","journal-title":"Pancreas"},{"key":"R23-20250824","first-page":"332","article-title":"Early gastroenteropancreatic neuroendocrine tumors: endoscopic therapy and surveillance","volume":"5","author":"Scher\u00fcbl","year":"1733","journal-title":"Visc Med 20"},{"key":"R25-20250824","doi-asserted-by":"crossref","first-page":"188637","DOI":"10.1016\/j.bbcan.2021.188637","article-title":"Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs","volume":"1876","author":"Shi","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R26-20250824","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1245\/s10434-019-07252-8","article-title":"Surgery for pancreatic neuroendocrine tumor g3 and carcinoma g3 should be considered separately","volume":"26","author":"Yoshida","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"R27-20250824","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1245\/s10434-019-08049-5","article-title":"Surgery with radical intent: is there an indication for G3 neuroendocrine neoplasms?","volume":"27","author":"Merola","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"R28-20250824","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.surg.2015.09.012","article-title":"Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: morphology matters","volume":"159","author":"Crippa","year":"2016","journal-title":"Surgery"},{"key":"R29-20250824","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.surg.2018.09.006","article-title":"Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors","volume":"165","author":"Tierney","year":"2019","journal-title":"Surgery"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000000336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T18:02:57Z","timestamp":1756058577000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000000336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000000336","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"2022-11-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}